
Dinesh Kadariya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/446232/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	171
2	Interleukinâ€1 Blockade Inhibits the Acute Inflammatory Response in Patients With STâ€6egment–Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014941.	3.7	150
3	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005036.	3.9	129
4	IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 381-384.	5.6	75
5	Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure. Journal of Cardiovascular Pharmacology, 2021, 77, 49-60.	1.9	65
6	Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. American Journal of Cardiology, 2018, 122, 1366-1370.	1.6	53
7	Dietary Fat, Sugar Consumption, andÂCardiorespiratoryÂFitness in PatientsÂWithÂHeartÂFailureÂWith PreservedÂEjectionÂFraction. JACC Basic To Translational Science, 2017, 2, 513-525.	4.1	51
8	Low <scp>NTâ€proBNP</scp> levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Failure, 2018, 5, 372-378.	3.1	50
9	Rationale and design of the Virginia Commonwealth University–Anakinra Remodeling Trialâ€3 (VCUâ€ART3): A randomized, placeboâ€controlled, doubleâ€blinded, multicenter study. Clinical Cardiology, 2018, 41, 1004-1008.	1.8	41
10	Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. American Journal of Cardiology, 2019, 123, 466-473.	1.6	36
11	Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF. JACC Basic To Translational Science, 2019, 4, 563-565.	4.1	28
12	The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The <scp>CANAâ€HF</scp> study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3335.	4.0	27
13	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. Diabetes, Obesity and Metabolism, 2018, 20, 2014-2018.	4.4	26
14	Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). Journal of Cardiovascular Pharmacology, 2019, 74, 266-269.	1.9	24
15	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. Frontiers in Cardiovascular Medicine, 2018, 5, 178.	2.4	21
16	Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work. Journal of Cardiovascular Pharmacology, 2018, 72, 68-70.	1.9	19
17	Determinants of Cardiorespiratory Fitness Following Thoracic Radiotherapy in Lung or Breast Cancer Survivors. American Journal of Cardiology, 2020, 125, 988-996.	1.6	17
18	Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction. Scientific Reports, 2022, 12, 1254.	3.3	15

Dinesh Kadariya

#	Article	IF	CITATIONS
19	Severely Impaired Cardiorespiratory Fitness in Patients With Recently Decompensated Systolic Heart Failure. American Journal of Cardiology, 2017, 120, 1854-1857.	1.6	10
20	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Design, Development and Therapy, 2017, Volume 11, 2121-2129.	4.3	10
21	Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. American Journal of Cardiology, 2020, 125, 76-81.	1.6	10
22	Potential role for interleukinâ€1 in the cardioâ€renal syndrome. European Journal of Heart Failure, 2019, 21, 385-386.	7.1	9
23	Association of Anti-Mullerian Hormone with C-Reactive Protein in Men. Scientific Reports, 2019, 9, 13081.	3.3	6
24	Comparison of Cardiorespiratory Fitness in Black or African American Versus Caucasian Patients With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2022, 42, 39-44.	2.1	6
25	Influence of extracellular volume fraction on peak exercise oxygen pulse following thoracic radiotherapy. Cardio-Oncology, 2022, 8, 1.	1.7	5
26	Time of eating and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction and obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2471-2473.	2.6	4
27	Midpoint of energy intake, non-fasting time and cardiorespiratory fitness in heart failure with preserved ejection fraction and obesity. International Journal of Cardiology, 2022, 355, 23-27.	1.7	4
28	Peak Oxygen Uptake Recovery Delay After Maximal Exercise in Patients With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2020, 40, 434-437.	2.1	3
29	Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure. American Journal of Cardiology, 2022, , .	1.6	1
30	Clinical features and outcomes between African American and Caucasian patients with Takotsubo Syndrome. Minerva Cardiology and Angiology, 2021, 69, 750-759.	0.7	0
31	Early changes in NT-proBNP levels predict new-onset heart failure in patients with STEMI. Minerva Cardiology and Angiology, 2020, , .	0.7	Ο